Grace Therapeutics
(NASDAQ) GRCE
Grace Therapeutics Financials at a Glance
Market Cap
$67.47M
Revenue (TTM)
$0.00
Net Income (TTM)
$6.84M
EPS (TTM)
$-0.36
P/E Ratio
-12.10
Dividend
$0.00
Beta (Volatility)
1.06 (Average)
Dividend
$0.00
Beta (Volatility)
1.06 (Average)
Price
$4.49
Volume
600,771.458
Open
$4.43
Price
$4.49
Volume
600,771.458
Open
$4.43
Previous Close
$4.49
Daily Range
$4.05 - $4.57
52-Week Range
$2.00 - $5.18
Dividend
$0.00
Beta (Volatility)
1.06 (Average)
Price
$4.49
Volume
600,771.458
Open
$4.43
Previous Close
$4.49
Daily Range
$4.05 - $4.57
52-Week Range
$2.00 - $5.18
GRCE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Grace Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
4
CEO
Prashant Kohli, MBA
Website
www.gracetx.comHeadquarters
Princeton, NJ 08540, US
GRCE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-10%
Return on Capital
-18%
Return on Assets
-10%
Earnings Yield
-8.26%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$67.47M
Shares Outstanding
15.47M
Volume
600.77K
Short Interest
0.00%
Avg. Volume
446.09K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$16.68M
EBITDA
$16.67M
Operating Cash Flow
$14.90M
Capital Expenditure
$0.00
Free Cash Flow
$14.90M
Cash & ST Invst.
$22.13M
Total Debt
$0.00
Grace Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$4.12K
N/A
Gross Margin
0.00%
N/A
Market Cap
$67.47M
N/A
Market Cap/Employee
$16.87M
N/A
Employees
4
N/A
Net Income
$3.18M
+23.6%
EBITDA
$3.36M
+9.3%
Quarterly Fundamentals
Net Cash
$18.67M
+68.9%
Accounts Receivable
$20.00K
-93.4%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-9.99%
N/A
Return on Invested Capital
-18.10%
N/A
Free Cash Flow
$2.22M
+46.1%
Operating Cash Flow
$2.22M
+46.1%